Renal Sympathetic Denervation in Patients With Chronic Kidney Disease and Resistant Hypertension

• Status: Unknown status
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To study whether renal sympathetic denervation(RSD) is safe and effective in patients with chronic kidney disease and resistant hypertension

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Criteria

Inclusion Criteria:

1. Subject is ≥ 18 and ≤75 years of age.

2. A serum creatinine level of 1.5 to 5.0 mg per deciliter (133 to 442 μmol per liter), a creatinine clearance of 20 to 70 ml per minute per 1.73 m2, with variations of less than 30 percent in the three months before randomization.

3. Persistent proteinuria (defined by urinary protein excretion of more than 0.3 g per day for three or more months which can evacuate urinary tract infection and overt heart failure [a New York Heart Association class of III or IV]).

4. Resistant hypertension.

5. Nondiabetic renal disease.

6. Subject is willing and able to comply with the protocol

7. Subject is expected to remain available for follow-up visits at the study center

8. Subject Informed Consent.

Exclusion Criteria:

1. Current treatment with corticosteroids, nonsteroidal antiinflammatory drugs, or immunosuppressive drugs.

2. Connective-tissue disease.

3. Obstructive uropathy.

4. Congestive heart failure (New York Heart Association class III or IV).

5. Subject has significant renovascular abnormalities (a history of prior renal artery intervention, including balloon angioplasty or stenting; double renal artery on one side, distortion, and extension ), measured by abdominal ultrasound or renal angiograms.

6. Subject has a history of myocardial infarction, unstable angina, cerebrovascular accident or alimentary tract hemorrhage in the previous 3 months.

7. Subject with sick sinus syndrome.

8. Subject has a history of allergy to contrast media; psychiatric disorders; drug or alcohol abuse; and pregnancy.

9. Enrolled in a concurrent study that may confound the results of this study